William Blair Initiates Coverage On IDEAYA Biosciences with Outperform Rating
William Blair analyst Alethia Young initiates coverage on IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform rating.
Stocks · News reference
IDEAYA Biosciences Q2 EPS $(1.22) Misses $(1.09) Estimate, Sales $8.857M Beat $5.015M Estimate
IDEAYA Biosciences (NASDAQ:IDYA) reported quarterly losses of $(1.22) per share which missed the analyst consensus estimate of $(1.09) by 11.93 percent. This is a 38.64 percent decrease over losses of $(0.88) per share
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Guggenheim Maintains Buy on IDEAYA Biosciences, Raises Price Target to $57
IDEAYA Biosciences Announced First Patient Has Been Dosed In The OptimUM-11 Phase 3 Registrational Trial Evaluating Darovasertib In Combination With Crizotinib For Patients With Primary Uveal Melanoma
Global Phase 3 registrational trial evaluating darovasertib, a first-in-class oral protein kinase C (PKC) inhibitor, in combination with crizotinib, an oral cMET inhibitor, as adjuvant therapy for patients with primary
Citizens Reiterates Market Outperform on IDEAYA Biosciences, Maintains $42 Price Target